Pair Name	Epigallocatechin gallate, Osimertinib
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Inhibition-->Glycolysis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Up-regulation	Activity	PRKAA1	hsa5562
	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	NCI-H1975	Gefitinib-resistant lung adenocarcinoma	Homo sapiens (Human)	N.A.
In Vivo Model	Human NCI-H1975 or AR cells were subcutaneously inoculated into the right flank of nude mice at a density of 2×10⁶ cells for H1975 and 5×10⁶ cells for AR, respectively. When the tumors grew to reach around 100 cm3 in volume, the animals were randomly divided into 6 groups with equal size (n = 5 mice per group) for treatment.
Result	The combined use of EGFR-TKIs and EGCG significantly reversed the Warburg effect by suppressing glycolysis while boosting mitochondrial respiration, which was accompanied by increased cellular ROS and decreased lactate secretion. The combination effectively activated the AMPK pathway while inhibited both ERK/MAPK and AKT/mTOR pathways, leading to cell cycle arrest and apoptosis, particularly in drug-resistant NSCLC cells. The in vivo results obtained from mouse tumor xenograft model confirmed that EGCG effectively overcame osimertinib resistance.